Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. Issue 8 (5th March 2018)

• Record Type: Journal Article
• Authors: Manna, Ida; Iaccino, Enrico; Dattilo, Vincenzo; Barone, Stefania; Vecchio, Eleonora; Mimmi, Selena; Filippelli, Enrica; Demonte, Giulio; Polidoro, Serena; Granata, Alfredo; Scannapieco, Sara; Quinto, Ileana; Valentino, Paola; Quattrone, Aldo
• Is Part Of: FASEB journal. Volume 32:Issue 8(2018)
• Page Start: 4241
• Page End: 4246
• Publication Date: 2018-03-05
• Subjects: exosomes -- biomarkers -- response to drugs; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201701533R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract : Multiple sclerosis (MS) is an autoimmune pathology leading to neurodegeneration. Because of the complexity and heterogenic etiology of this disease, diagnosis and treatment for individual patients are challenging. Exosome‐associated microRNAs (miRNAs) have recently emerged as a new class of diagnostic biomarkers involved in both autoimmune and neurologic disorders. Interesting new evidence has emerged showing that circulating miRNAs are dysregulated in MS body fluids, including serum, plasma, and cerebrospinal fluid. We hypothesized that exosome‐associated miRNAs could present a readily accessible blood‐based assay for MS disease. We detected expression of miRNAs by quantitative PCR on a small cohort of MS patients. We analyzed circulating exosome‐associated miRNAs of MS patients before and after therapy and found that 14 exosome‐associated miRNAs were significantly down‐regulated, while 2 exosome‐associated miRNAs were significantly up‐regulated in IFN‐β‐treated relapsing‐remitting MS patients with response to therapy compared to those without response. We identified a serum miRNA panel that could be used to monitor the response to IFN‐β therapy. Overall, these data suggest that circulating exosome‐associated miRNA profiling could represent an easily detectable biomarker of disease and treatment response.—Manna, I., Iaccino, E., Dattilo, V., Barone, S., Vecchio, E., Mimmi, S., Filippelli, E., Demonte, G., Polidoro, S., Granata, A., Scannapieco, S., Quinto, I., Valentino, P., Quattrone, A. Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB J . 32, 4241–4246 (2018). www.fasebj.org